MedTrace Logo

Clinical Application of CTDNA in Operable Breast Cancer Patients

NCT02797652 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-06-14

No results posted yet for this study

Summary

Our study aims to evaluate the possibility of clinical application of CTDNA detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or indicators of early diagnosis, therapy efficiency, or postoperative surveillance of breast cancer.

Conditions

Interventions

PROCEDURE

Neoadjuvant chemotherapy before surgery

The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.

PROCEDURE

Surgery followed by adjuvant chemotherapy

The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Qiang Sun, Doctor · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02797652 on ClinicalTrials.gov